Read Our Latest Issue Is a runaway immune reaction making a dengue vaccine dangerous? In December 2015 then president Benigno Aquino III of the Philippines and others negotiated a deal with pharmaceutical company Sanofi to purchase three million doses of Dengvaxia, the first vaccine ever licensed for dengue. The plan was to give a million schoolchildren, nine years of age, three doses of the vaccine each, sparing them from the worst outcomes of dengue: shock, organ failure and death. This is a preview. Make a selection below to access this issue.Already have access? . Having trouble accessing this article? Please visit our page for more information Discover world-changing science. Explore our digital archive back to 1845, including articles by more than 150 Nobel Prize winners. Follow us Scientific american arabic (c) 2021 Scientific American, a Division of Springer Nature America, Inc. All Rights Reserved. Support our award-winning coverage of advances in science & technology. Already a subscriber? Subscribers get more award-winning coverage of advances in science & technology.